Evidence map›Paper›PMID 31548551›Full record

ArticleScientific reports2019

First demonstration of protective effects of purified mushroom polysaccharide-peptides against fatty liver injury and the mechanisms involved.

Shuang Zhao, Shuman Zhang, Weiwei Zhang, Yi Gao, Chengbo Rong, Hexiang Wang, Yu Liu, Jack Ho Wong, Tzibun Ng

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Sublingual Dripping Pill Formulation ofCurrent issues in molecular biology · 2025
    Article
  3. Review
  4. Therapeutic efficacy of a galactoglucan fromFrontiers in nutrition · 2025
    Article
  5. Article
  6. A novel mushroom (Frontiers in nutrition · 2023
    Article
  7. Oligochitosan Synthesized byMolecules (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Shuang ZhaoInstitute of Plant and Environment Protection, Beijing Academy of Agriculture and Forestry Sciences, Beijing, 100097, China.
Shuman ZhangInstitute of Plant and Environment Protection, Beijing Academy of Agriculture and Forestry Sciences, Beijing, 100097, China.
Weiwei ZhangInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, China.
Yi GaoBeijing Xicheng District Health Care Center for Mothers and Children, Beijing, 100053, China.
Chengbo RongInstitute of Plant and Environment Protection, Beijing Academy of Agriculture and Forestry Sciences, Beijing, 100097, China.
Hexiang WangState Key Laboratory for Agrobiotechnology and Department of Microbiology, China Agricultural University, Beijing, 100193, China. hxwang@cau.edu.cn.
Yu LiuInstitute of Plant and Environment Protection, Beijing Academy of Agriculture and Forestry Sciences, Beijing, 100097, China.
Jack Ho WongSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China. jack1993@yahoo.com.
Tzibun NgSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China. b021770@mailserv.cuhk.edu.hk.
Beijing Academy of Agricultural and Forestry Sciences · CNChinese University of Hong Kong · CNBeijing Children’s Hospital · CNChina Agricultural University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNMinistry of Agriculture and Rural Affairs · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fatty liver (FLD) disease is a consequence of metabolic syndrome, which is a health problem worldwide with a phenomenal rise in prevalence. In this study, two hepatoprotective polysaccharide-peptides were extracted from the mushroom Auricularia polytricha followed by chromatographic fractionation of the extract on the ion exchanger DEAE-cellulose and gel filtration on Sephadex-200 to yield two purified fractions: APPI and APPII. The monosaccharide compositions, FT-IR, N-terminal sequences, internal peptide sequences and molecular weights of the two fractions were determined. Furthermore, their hepatoprotective effect on human hepatoma HepG2 cells in vitro and in an animal model of fatty liver disease was evidenced by the findings that APPI and APPII diminished lipid deposit in cells, blood and the liver, increased cellular antioxidant activity and viability, and protected the liver against injury. The mechanistic study revealed that APPI and APPII activated the adiponectin pathway, up-regulated expression of genes controlling free fatty acid (FFA) oxidation, such as AMPK, CPTl, ACOX1 and PPARα genes, enhanced lipid metabolism, preserved hepatic function, promoted the antioxidant defense system and reduced lipid peroxidation. Hence the bioactive compounds of A. polytricha could serve as therapeutic agents in the food and pharmaceutical industries.

Indexed as

AgaricalesAnimalsBiological ProductsDisease Models, AnimalFatty Acids, NonesterifiedFatty LiverHep G2 CellsHumansLipid MetabolismLiverMaleProtective AgentsRatsRats, WistarBiological ProductsFatty Acids, NonesterifiedProtective Agents

Identifiers

PMID31548551
PMCPMC6757109
OpenAlexW2974055174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.